2023
Characterization of Patients with Metastatic Renal Cell Carcinoma Undergoing Deferred, Upfront, or No Cytoreductive Nephrectomy in the Era of Combination Immunotherapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium
Takemura K, Ernst M, Navani V, Wells J, Bakouny Z, Donskov F, Basappa N, Wood L, Meza L, Pal S, Szabados B, Powles T, Beuselinck B, McKay R, Lee J, Ernst D, Kapoor A, Yuasa T, Choueiri T, Heng D. Characterization of Patients with Metastatic Renal Cell Carcinoma Undergoing Deferred, Upfront, or No Cytoreductive Nephrectomy in the Era of Combination Immunotherapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. European Urology Oncology 2023, 7: 501-508. PMID: 37914579, DOI: 10.1016/j.euo.2023.10.002.Peer-Reviewed Original ResearchMetastatic renal cell carcinomaInternational mRCC Database ConsortiumCytoreductive nephrectomySystemic therapy initiationMetastatic kidney cancerRenal cell carcinomaCombination immunotherapyDeferred CNUpfront CNCN statusPrimary tumorOverall survivalTherapy initiationCell carcinomaInternational Metastatic Renal Cell Carcinoma Database ConsortiumAdvent of novel therapeutic agentsKidney cancerInitiation of systemic therapyDiagnosis of metastatic diseaseTreatment of choiceProportion of patientsCox proportional-hazards regressionCharacterization of patientsIO-based combinationsProportional-hazards regression
2021
Radiomic features of renal cell carcinoma primary and metastatic sites as predictors of TERT and BAP1 mutations.
Meza L, Filippov A, Naim S, Dizman N, Chehrazi-Raffle A, Philip E, Maholtra J, Muddasani R, Chawla N, Wong C, Salgia S, Karimi M, Trent J, Byron S, Chaudhry A, Pal S. Radiomic features of renal cell carcinoma primary and metastatic sites as predictors of TERT and BAP1 mutations. Journal Of Clinical Oncology 2021, 39: 282-282. DOI: 10.1200/jco.2021.39.6_suppl.282.Peer-Reviewed Original ResearchMetastatic renal cell carcinomaMetastatic sitesRenal cell carcinomaBAP1 mutationsWhole-exome sequencingRadiomic featuresCell carcinomaNon-invasive methodPrimary tumorTERT mutationsClear cell histologyPoor clinical outcomeRoutine clinical careMajority of ptsCell histologyClinical outcomesPrimary lesionClinical careMutation statusMutational statusSignificant associationCT imagingExome sequencingRadiomics analysisCancer Imaging Archive